PROTAC TG2 degrader-1

PROTAC TG2 degrader-1 (compound 11) (0.1-10 μM; 6-24 h) induces concentration-dependent degradation of TG2 in OVCAR5 human ovarian cancer cells at 6 h after a single administration, while intermittent repeated administration within 24 h sustains the reduction of TG2 protein levels^[1].
PROTAC TG2 degrader-1 (1-10 μM; 6-24 h) induces concentration-dependent degradation of TG2 in human ovarian cancer SKOV3 cells at 6 h after a single administration, and repeated intermittent administration within 24 h sustains the reduction of TG2 protein levels^[1].
PROTAC TG2 degrader-1 (0.1-30 μM; 2-24 h) induces TG2 protein degradation in a time- and concentration-dependent manner^[1].
PROTAC TG2 degrader-1 directly binds to purified full-length human TG2 with a K_d of 68.9 μM^[1].
PROTAC TG2 degrader-1 (10 μM; 6-18 h) significantly reduces the fibronectin adhesion capacity and migration ability of human ovarian cancer cell lines OVCAR5 and SKOV3^[1].
PROTAC TG2 degrader-1 (0.1-30 μM; 5 days) does not exert significant cytotoxicity in OVCAR5 and SKOV3 human ovarian cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.